Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant

The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025

Zydus and CSIR-CDRI Lucknow to develop drug for CKD induced Osteoporosis

Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism

MGC inks agreement to revolutionize allergy care

Sun Pharmaceutical receives USFDA approval for oral JAK inhibitor ‘Leqselvi’

Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials

Avallano releases AI-driven ProtocolCopilot

ProtocolCopilot leverages advanced artificial intelligence to streamline the process of understanding and adhering to clinical research protocols

Avallano appoints Michael A. Ibara as Chief Strategy Officer

Ibara will drive AI-powered clinical research innovation

MediPharm Labs acquires advanced medical cannabis delivery method technology from Remidose Aerosols

Transaction is non-dilutive, with 100% performance-based payment through a royalty model

Pfizer updates on Phase 3 study of investigational gene therapy for ambulatory boys with Duchenne Muscular Dystrophy

The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment

Merck's oncology pipeline of DDRi and ADC poised to advance cancer treatment

Merck shared updates on the company’s oncology pipeline and focused R&D approach

FDA grants priority review to Merck’s application for Keytruda plus chemotherapy for metastatic malignant pleural mesothelioma

Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients